519 672 2121
519 672 2121
Toggle mobile menu
Book a Consultation
Close mobile menu

*** IMPORTANT *** 

A settlement agreement was reached to settle all class actions filed in Canada. For more information, please see the “Developments” section below. 

On July 26, 2018, the Superior Court of Quebec authorized the pharmaceutical class action lawsuit filed by Siskinds Desmeules against the defendant Bayer, inc. (“defendant”), the manufacturer of the birth control drugs Yasmin and Yaz. The lawsuit alleges that Bayer failed to adequately disclose the health risks linked to these products, regarding venous thromboembolism (VTE), arterial thromboembolism (ATE) and gallbladder disease.

Québec class action for Yasmin/Yaz users and their families 

The class action was authorized on behalf of all persons residing in Quebec who were prescribed and ingested the drugs Yasmin and/or Yaz, from the respective introduction of these drugs on the market (December 10, 2004 for Yasmin and January 6, 2009 for Yaz) and the date of November 30, 2011, and who were diagnosed with deep vein thrombosis, pulmonary embolism, arterial thromboembolism or gallbladder disease. 

This class also concerns estates, assigns, family members and dependants of persons described above,  ensuring broader legal protection and compensation rights for families who suffered loss or harm. 

Compensation for affected class members 

The class action seeks to obtain damages from the defendant in order to compensate the Class members for the damages suffered from the diagnosis of deep vein thrombosis, pulmonary embolism, arterial thromboembolism or gallbladder disease., allegedly resulting from the use of Yasmin and/or Yaz. 

The court has not yet decided whether the defendant has committed a fault and the defendant is contesting the class action. 

Similar class actions against Bayer were also filed elsewhere in Canada, including in Ontario and in Saskatchewan.

Are you eligible for this class action?

Think you may be a member of the Yasmin/Yaz birth control class action, or know someone who might be?

Email us today

Need more information?

Please email [email protected] or call us at 418.694.2009 or toll-free at 1.877.735.3842 to learn more about the Yasmin/Yaz class action.

Developments

Yasmin/Yaz class action authorized 

In July 26, 2018, the Superior Court of Québec authorized the bringing of a class action against the defendant on behalf of all persons residing in Québec who were prescribed and ingested the oral contraceptives Yasmin and/or Yaz and who were diagnosed with deep vein thrombosis, pulmonary embolism, arterial thromboembolism or gallbladder disease, and their families. The Court’s decision is available here.

In November 15, 2018, the Québec Court of Appeal dismissed the application brought by the defendant for leave to appeal from the authorization order rendered by Justice Beaugé. Accordingly, the authorization order became final. The decision of the Court of Appeal is available here.

Originating application filed and court hearing 

In February 15, 2019, following the authorization, an originating application was filed.

On August 19, 2021, judgment was rendered on a motion to strike the defendant's allegations and specifications. The Court’s decision is available here.

On September 2, 2021, the originating application was amended. This motion is available here.

The Yasmin/Yaz birth control class action is now moving towards a hearing on the merits.

Settlement agreement reached

On November 14, 2025, the approval hearings for the Settlement Agreement and Class Counsel’s fees were held before the courts of Ontario and Québec. The Settlement Agreement and Class Counsel’s fees were approved by both courts, as reflected in the judgments issued on November 26 and 27, 2025. These judgments are available in our Documents section.

The hearing for Saskatchewan has been rescheduled to February 11, 2026. Members of the Saskatchewan Class, meaning any resident of Canada except those in Ontario and Québec, have until January 15, 2026, at 5:00 p.m. to object to the Settlement Agreement, if applicable. You can consult the amended notices in our Documents section.

 

On July 30, 2025, the parties to all the class actions across Canada have signed a settlement agreement to put an end to the various disputes concerning the contraceptive pills Yasmin and YAZ and the alleged risks of venous thromboembolism, arterial thromboembolism, and gallbladder disease. The settlement agreement is available here. 

Class members had until October 14, 2025, to object to the Settlement and Class counsel’s fee. 

This settlement provides for the payment of a lump sum of $9,050,000 by Bayer, Inc., without admission of liability. The settling class members will need to file a claim to obtain advantages from the sum. The advantages will be distributed according to a point system detailed in the Compensation and distribution protocol. The Compensation and distribution protocol is available here.  

The settlement agreement must be approved by the courts of Ontario, Quebec and Saskatchewan to come into effect.  

A joint hearing for Ontario and Quebec was held on November 14, 2025, to seek approval of the Settlement agreement and Class counsel’s fees. Approval was rendered on Novembre 26, 2025, by the Superior Court of Quebec and on November 27, 2025, by the Ontario Superior Court of Justice.  

The hearing for Saskatchewan has been rescheduled to February 11, 2026. Members of the Saskatchewan Class, meaning any resident of Canada except those in Ontario and Québec, have until January 15, 2026, at 5:00 p.m. to object to the Settlement Agreement, if applicable. You can consult the amended notices in our Documents section. 

FAQs

What should I do to protect my rights?

To protect your rights, you should:

  1. Obtain all pharmaceutical or medical records that prove the prescription and ingestion of Yasmin and/or Yaz ;
  2. Obtain all r medical records that prove the diagnosis of deep vein thrombosis, pulmonary embolism, arterial thromboembolism or gallbladder disease ; and
  3. Contact us to register to our database and receive updates on this case. 

You may contact Siskinds Desmeules so that we can assist you in obtaining your relevant medical and pharmaceutical records. The more time passes, the more difficult it may become to gather this information. 

All personal information provided to Siskinds Desmeules regarding your injuries/symptoms will remain private and confidential. 

I still have a question. Who should I contact?

For answers to common questions about class actions in Canada, such as timelines, eligibility, and settlement information, please visit our Class Action Lawsuit FAQ page.

If you have any additional questions, you can contact us by email at [email protected] or call us toll-free at 1.877.735.3842.

Documents

Settlement agreement 

Proceedings 

Yasmin/Yaz class action authorized 

In July 26, 2018, the Superior Court of Québec authorized the bringing of a class action against the defendant on behalf of all persons residing in Québec who were prescribed and ingested the oral contraceptives Yasmin and/or Yaz and who were diagnosed with deep vein thrombosis, pulmonary embolism, arterial thromboembolism or gallbladder disease, and their families. The Court’s decision is available here.

In November 15, 2018, the Québec Court of Appeal dismissed the application brought by the defendant for leave to appeal from the authorization order rendered by Justice Beaugé. Accordingly, the authorization order became final. The decision of the Court of Appeal is available here.

Originating application filed and court hearing 

In February 15, 2019, following the authorization, an originating application was filed.

On August 19, 2021, judgment was rendered on a motion to strike the defendant's allegations and specifications. The Court’s decision is available here.

On September 2, 2021, the originating application was amended. This motion is available here.

The Yasmin/Yaz birth control class action is now moving towards a hearing on the merits.

Settlement agreement reached

On November 14, 2025, the approval hearings for the Settlement Agreement and Class Counsel’s fees were held before the courts of Ontario and Québec. The Settlement Agreement and Class Counsel’s fees were approved by both courts, as reflected in the judgments issued on November 26 and 27, 2025. These judgments are available in our Documents section.

The hearing for Saskatchewan has been rescheduled to February 11, 2026. Members of the Saskatchewan Class, meaning any resident of Canada except those in Ontario and Québec, have until January 15, 2026, at 5:00 p.m. to object to the Settlement Agreement, if applicable. You can consult the amended notices in our Documents section.

 

On July 30, 2025, the parties to all the class actions across Canada have signed a settlement agreement to put an end to the various disputes concerning the contraceptive pills Yasmin and YAZ and the alleged risks of venous thromboembolism, arterial thromboembolism, and gallbladder disease. The settlement agreement is available here. 

Class members had until October 14, 2025, to object to the Settlement and Class counsel’s fee. 

This settlement provides for the payment of a lump sum of $9,050,000 by Bayer, Inc., without admission of liability. The settling class members will need to file a claim to obtain advantages from the sum. The advantages will be distributed according to a point system detailed in the Compensation and distribution protocol. The Compensation and distribution protocol is available here.  

The settlement agreement must be approved by the courts of Ontario, Quebec and Saskatchewan to come into effect.  

A joint hearing for Ontario and Quebec was held on November 14, 2025, to seek approval of the Settlement agreement and Class counsel’s fees. Approval was rendered on Novembre 26, 2025, by the Superior Court of Quebec and on November 27, 2025, by the Ontario Superior Court of Justice.  

The hearing for Saskatchewan has been rescheduled to February 11, 2026. Members of the Saskatchewan Class, meaning any resident of Canada except those in Ontario and Québec, have until January 15, 2026, at 5:00 p.m. to object to the Settlement Agreement, if applicable. You can consult the amended notices in our Documents section. 

What should I do to protect my rights?

To protect your rights, you should:

  1. Obtain all pharmaceutical or medical records that prove the prescription and ingestion of Yasmin and/or Yaz ;
  2. Obtain all r medical records that prove the diagnosis of deep vein thrombosis, pulmonary embolism, arterial thromboembolism or gallbladder disease ; and
  3. Contact us to register to our database and receive updates on this case. 

You may contact Siskinds Desmeules so that we can assist you in obtaining your relevant medical and pharmaceutical records. The more time passes, the more difficult it may become to gather this information. 

All personal information provided to Siskinds Desmeules regarding your injuries/symptoms will remain private and confidential. 

I still have a question. Who should I contact?

For answers to common questions about class actions in Canada, such as timelines, eligibility, and settlement information, please visit our Class Action Lawsuit FAQ page.

If you have any additional questions, you can contact us by email at [email protected] or call us toll-free at 1.877.735.3842.

Settlement agreement 

Proceedings 

Contact Us

Join to stay informed about the progress of this class action.

Your information will be maintained and used in accordance with our privacy notice. Completing this form does not create a lawyer-client relationship with Siskinds LLP or Siskinds Desmeules s.e.n.c.r.l. or any of their personnel, nor does it impose any obligations related to the class action or otherwise.

There Was An Error